5-MeO-DMT

In a conversation with Interview Magazine, legendary boxer Mike Tyson opened up to actress and boxing aficionado Rosie Perez about his surprising return to the ring at age 58. But beyond his upcoming bout against YouTuber-turned-boxer Jake Paul, it was Tyson's profound experiences with psychedelics...

Private psychedelics medicine company Beckley Psytech confirmed Monday that the first patient has been dosed in a new research study investigating the neurophysiological effects of BPL-003, the company's novel synthetic intranasal formulation of 5-MeO-DMT (also known as mebufotenin), on the human...

Private psychedelics medicine company Beckley Psytech Ltd announced this week that the first patient has been dosed in the second part of its two-part Phase IIa study evaluating BPL-003 in patients with treatment-resistant depression (TRD). BPL-003 is its proprietary...

Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.)  See: Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics...

Nasdaq-listed, GH Research (NASDAQ:GHRS) is a clinical-stage biopharma business developing novel 5-MeO-DMT therapies as transformative treatment of psychiatric and neurological disorders. Its reported yearly financial results show: Cash position of $ 222.7 million by December 31, 2023, an 11.5%...

Biopharma and resources-pooling company Atai Life Sciences (NASDAQ: ATAI) has invested a total of $50 million in Beckley Psytech Ltd., a U.K.-based clinical-stage biotech advancing short-duration psychedelics for neuropsychiatric conditions. Following the investment -$40 million direct and an...

The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its  financial results for Q3 2023 ended September 30, showing: Cash, cash equivalents and other financial assets and marketable securities totaled $228.7 million by Sept. 30, compared to $251.7 million by...

After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s (NASDAQ: GHRS) Investigational New Drug (IND) application for a Phase 1 clinical trial of proprietary inhalable 5-MeO-DMT compound GH001 on clinical hold due to “insufficient...

GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading psychedelics stocks listed in Nasdaq, shared its financial results and business updates for its second...

The following is Part II of our Tandava coverage. For Part I, click here. Mexico-based retreats center Tandava is launching a series of offerings focused on helping specific communities on their healing paths, supported with 5-MeO-DMT therapy. Along with the BIPOC community retreat, September...

The following is Part I of our Tandava coverage. For Part II, click here. Psychedelics are often being used as medicines to help cope with a variety of situations and conditions that life throws our way. Considering the substances are still illegal in most countries, including the U.S., retreat...

GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023. The company is developing a proprietary 5-MeO-DMT formulation primarily targeting Treatment-Resistant Depression (TRD). Numbers show: Total...

Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound 5-MeO-DMT, for Treatment-Resistant Depression (TRD). Dr. Rob Conley, chief scientific officer at...

Clinical-stage private biotech company Beckley Psytech Ltd has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment.  CEO ‍Cosmo Feilding Mellen said the company’...

Two psychedelics companies have shared their updates and key milestones to be reached this 2023. The 5-MeO-DMT Business Clinical-stage biopharma company GH Research PLC (NASDAQ: GHRS) has received initial regulatory and ethical approvals to commence a multi-site Phase 2b trial for its lead product...